glutathione hplc analysis of the profiles in the R. diobovatum Development and validation of a

BARD has been shown to increase estimated GFR and preserve kidney function in stage 4 CKD patients

Pharmaceutical Grade article covers the quality gap in detail

Imaging 40 : 144511452 (2014)

A product may demonstrate: Better stability in a laboratory Higher blood levels after a dose Increased glutathione in selected cells Changes in an oxidative-stress biomarker Those findings can be meaningful, but they do not automatically prove that the product: Improves energy or cognition Prevents cardiovascular or neurodegenerative disease Detoxifies the body in a clinically meaningful way Treats chronic illness Slows biological aging Improves longevity Those larger claims require controlled clinical trials measuring patient-important outcomes

Targets : Uneven skin tone, dull skin, pigmentation, melasma, acne marks, PIH

Mahadevappa R, Ma R, Kwok HF